VDPHL01

Phase 3Small molecule

VVeradermics, Inc.

VDPHL01 is one of 88 small molecule programs targeting Androgenetic Alopecia (AGA). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic Alopecia (AGA)Active, not recruiting

Safety and EfficacyActive, not recruiting

Efficacy and SafetyActive, not recruiting

Androgenetic Alopecia (AGA)Phase 3

Active, not recruiting

Safety and EfficacyPhase 3

Active, not recruiting

Efficacy and SafetyPhase 3

Active, not recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Savaysa

Daiichi Sankyo

Phase 3

3 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 3

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 4

Busulfex

Akero Therapeutics

Phase 3

3 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 6

Oxycontin

PPurdue Pharma LP

Phase 3

1 7

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 8

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 9

Avalglucosidase Alfa

Sanofi

Phase 3

1 10

Becotatug Vedotin

FFudan University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Safety and Efficacy

NCT06972264

Q1 2028

Phase 3Active, not recruiting

Androgenetic Alopecia (AGA)

NCT07146022

Clinical

Trials by Indication[1]

Safety and Efficacy2 trials

Safety and Efficacy of VDPHL01 in Males and Females With AGA

Active, not recruiting·VVeradermics, Inc.·Phase 2·NCT06527365·70 enrolled

Safety and Efficacy of VDPHL01 in Males With AGA

Active, not recruiting·VVeradermics, Inc.·Phase 3·NCT06972264·480 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of VDPHL01 in Males With AGA

Active, not recruiting·VVeradermics, Inc.·Phase 2/3·NCT06724614·480 enrolled

Androgenetic Alopecia (AGA)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia

Active, not recruiting·VVeradermics, Inc.·Phase 3·NCT07146022·552 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VDPHL01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VDPHL01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VDPHL01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veradermics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVeradermics, Inc.

VDPHL01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Trials by Indication[1]

Safety and Efficacy2 trials

Efficacy and Safety1 trial

Androgenetic Alopecia (AGA)1 trial

References

Drug Info

Quick Facts

Related News